Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.54 |
| ▸ | SKP1 | P63208 | 2/20 | 0.54 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 3/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27838527 | 0.86 | MET (0.47) | METMAPTLMNAMEN1KMT2A | |
| SCHEMBL1686077 | 0.85 | CKS1B (0.56) | CKS1BSKP1SKP2PDK2PIK3CA | |
| SCHEMBL2958371 | 0.82 | CKS1B (0.55) | CKS1BSKP1SKP2PDK2PIK3CA | |
| SCHEMBL1686099 | 0.81 | CKS1B (0.52) | CKS1BSKP1SKP2PDK2PIK3CA | |
| SCHEMBL1686153 | 0.81 | CKS1B (0.52) | CKS1BSKP1SKP2PDK2KIT | |
| SCHEMBL1686109 | 0.80 | CKS1B (0.50) | CKS1BSKP1SKP2PDK2KIT | |
| SCHEMBL1686128 | 0.78 | CKS1B (0.48) | CKS1BSKP1SKP2PDK2KIT | |
| SCHEMBL1686081 | 0.78 | CKS1B (0.57) | CKS1BSKP1SKP2PDK2PIK3CA | |
| SCHEMBL3060483 | 0.78 | CKS1B (0.60) | CKS1BSKP1SKP2PIK3CAKIT | |
| SCHEMBL1686116 | 0.77 | CKS1B (0.47) | CKS1BSKP1SKP2PDK2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307374-B1 | PIPERAZIN-1-YL-TRIFLUOROMETHYL-SUBSTITUTED-PYRIDINES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| EP-2307374-B1 | PIPERAZIN-1-YL-TRIFLUOROMETHYL-SUBSTITUTED-PYRIDINES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| US-8895562-B2 | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-8895562-B2 | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-8895562-B2 | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-20110130408-A1 | PIPERAZIN-1-YL-TRIFLUOROMETHYL-SUBSTITUTED-PYRIDINES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAGE S.A., EDIFICIO JOHNSON & JOHNSON (ES) | 2011-06-02 | — | — | US | disclosed |
| US-20110130408-A1 | PIPERAZIN-1-YL-TRIFLUOROMETHYL-SUBSTITUTED-PYRIDINES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAGE S.A., EDIFICIO JOHNSON & JOHNSON (ES) | 2011-06-02 | — | — | US | disclosed |
| US-20110130408-A1 | PIPERAZIN-1-YL-TRIFLUOROMETHYL-SUBSTITUTED-PYRIDINES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAGE S.A., EDIFICIO JOHNSON & JOHNSON (ES) | 2011-06-02 | — | — | US | disclosed |
| EP-2307374-A1 | PIPERAZIN-1-YL-TRIFLUOROMETHYL-SUBSTITUTED-PYRIDINES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010012758-A1 | PIPERAZIN-1-YL-TRIFLUOROMETHYL-SUBSTITUTED-PYRIDINES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130408-A1 | PIPERAZIN-1-YL-TRIFLUOROMETHYL-SUBSTITUTED-PYRIDINES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | GRIN2C, DRD2, GRIN2A | CKS1B 761/4885SKP1 241/4885SKP2 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.